TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18039501

Group type: EXPERIMENTAL
Intervention: Selenium as sodium selenite (4000 microg on the first day, 1000 microg/day for the next 9 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose selenium administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous administration of selenium
Number of subjects: 0
Study: 16128875

Group type: EXPERIMENTAL
Intervention: Isotonic muscle stretch (with and without weight bearing)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Isokinetic muscle stretch
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 87
Study: 12034949

Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg intravenously)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study: 9807972

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 7667771

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 345
Study: 2681320

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 331

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 331
Study: 816842

Group type: EXPERIMENTAL
Intervention: 20 mg of disodium cromoglycate (DSCG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg of disodium cromoglycate (DSCG)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 20 mg of disodium cromoglycate (DSCG) four times daily for 2 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6453695

Group type: EXPERIMENTAL
Intervention: 3% benzoyl peroxide gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10% benzoyl peroxide gel
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stronger or milder concentration of benzoyl peroxide gel
Number of subjects: 50
Study: 31269122

Group type: EXPERIMENTAL
Intervention: Menthol package (lip hydration and ice popsicles)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-menthol measures (lip hydration and ice popsicles)
Number of subjects: 120
Study: 29016980

Group type: EXPERIMENTAL
Intervention: Stepped Care (initial 20-min of behavioural change counselling, followed by three sessions of Motivational Enhancement Therapy and referral to local alcohol services)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimal Intervention (5-min of brief advice)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimal Intervention
Number of subjects: 100
Study: 25633662

Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 137

Group type: COMPARATOR
Intervention: linagliptin 5 mg
Number of subjects: 137
Study: 24382548

Group type: EXPERIMENTAL
Intervention: Surface Electrical Stimulation Group (SESG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravaginal Electrical Stimulation Group (IVESG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study: 22474066

Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg once daily for 4 weeks (non-atorvastatin group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg twice daily for 4 weeks (non-atorvastatin group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg daily (control group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 4 weeks (control group)
Number of subjects: 24
Study: 19938918

Group type: EXPERIMENTAL
Intervention: Alcohol (mean Blood Alcohol Concentration [BAC] = .10) with enhanced self-focused attention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Veridical control drink with enhanced self-focused attention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol (mean Blood Alcohol Concentration [BAC] = .10) without enhanced self-focused attention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Veridical control drink without enhanced self-focused attention
Number of subjects: 40
Study: 17468881

Group type: EXPERIMENTAL
Intervention: Fatigue trial of 30‐s maximal static exercise of the knee flexors
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 16
Study: 14737854

Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 11335697

Group type: EXPERIMENTAL
Intervention: Proton MR spectroscopy with metabolite-nulling in acute lesions
Number of subjects: 30
Study: 9727782

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (3 mL, 3.2% solution, 95 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nebulized salbutamol (3 mL, 2.5 mg)
Number of subjects: 33
Study: 8001355

Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease activity index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopy and pH monitoring
Number of subjects: 0
Study: 3241289

Group type: EXPERIMENTAL
Intervention: Methylphenobarbital (MPB) 3 x 10 mg/kg on the first day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31822498

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg) in combination with taselisib (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of enzalutamide and taselisib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzalutamide and taselisib in Luminal AR (LAR) TNBC subtype
Number of subjects: 0
Study: 31055061

Group type: EXPERIMENTAL
Intervention: NMT (Neuromuscular Training) program for 8 weeks, 6 weeks of which included 18 sessions lasting approximately 30 minutes each
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 27838369

Group type: EXPERIMENTAL
Intervention: Tele-exercise group (supervised resistance exercise at home for 20-40 min, three times per week for 12 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tele-exercise group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (maintained lifestyle without intervention)
Number of subjects: 23
Study: 25451617

Group type: EXPERIMENTAL
Intervention: Mother-infant psychoanalytic treatment (MIP group)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Child Health Center care (CHCC group)
Number of subjects: 66
Study: 23551822

Group type: COMPARATOR
Intervention: Non-alcohol (BAC equal to 0‰)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Legal alcohol (BAC greater than 0 up to 0.8‰)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Illegal alcohol (BAC greater than 0.8‰)
Number of subjects: 499
Study: 20929723

Group type: EXPERIMENTAL
Intervention: APF + PD
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: APF + FD
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1100‐ppm‐F dentifrice (FD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo dentifrice (PD)
Number of subjects: 12
Study: 19423387

Group type: EXPERIMENTAL
Intervention: Real rTMS on primary motor cortex (M1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Real rTMS on calcarine cortex
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 29
Study: 16682727

Group type: EXPERIMENTAL
Intervention: Oral topotecan 2.3 mg/m2/d on days 1 to 5
Number of subjects: 829

Group type: COMPARATOR
Intervention: Intravenous docetaxel 75 mg/m2 day 1 every 21 days
Number of subjects: 829
Study: 16281645

Group type: EXPERIMENTAL
Intervention: Care plan
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study: 10469815

Group type: EXPERIMENTAL
Intervention: ZDV plus ddI combination therapy
Number of subjects: 831

Group type: COMPARATOR
Intervention: ZDV monotherapy
Number of subjects: 831

Group type: COMPARATOR
Intervention: ddI monotherapy
Number of subjects: 831
Study: 8915214

Group type: EXPERIMENTAL
Intervention: Covered Wallstent
Number of subjects: 40
Study: 1856814

Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6849160

Group type: EXPERIMENTAL
Intervention: Disulfiram 400 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31829248

Group type: EXPERIMENTAL
Intervention: Landiolol administration for three days during the perioperative period
Number of subjects: 400

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 400
Study: 29289374

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg qhs
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 27754700

Group type: EXPERIMENTAL
Intervention: MPH-MLR (Methylphenidate HCl Extended-Release)
Number of subjects: 256
Study: 23786900

Group type: EXPERIMENTAL
Intervention: Synbiotic food
Number of subjects: 62
Study: 21070566

Group type: EXPERIMENTAL
Intervention: Transanal manual repair (group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Transanal stapled repair (group 2)
Number of subjects: 45
Study: 20537810

Group type: EXPERIMENTAL
Intervention: Gradual cessation with nicotine lozenge (via mail)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Abrupt cessation
Number of subjects: 746

Group type: COMPARATOR
Intervention: Minimal treatment
Number of subjects: 746
Study: 18546662

Group type: EXPERIMENTAL
Intervention: Checkerboard with alternated dark and light shapes superimposed on the corners of the squares
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theories of boundary completion and edge propagation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactions sensitive to contrast sign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Café Wall illusion hypothesis
Number of subjects: 0
Study: 15940624

Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon and lamivudine)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Log intrahepatic cccDNA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Log intrahepatic HBV DNA
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Log cccDNA at -0.80 copies/genome equivalent
Number of subjects: 47
Study: 12900381

Group type: EXPERIMENTAL
Intervention: Isoproterenol (1 microM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Epinephrine (10 microM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Epinephrine (10 microM) with phentolamine (100 microM)
Number of subjects: 8
Study: 10100770

Group type: EXPERIMENTAL
Intervention: Once-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Number of subjects: 514

Group type: COMPARATOR
Intervention: Twice-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Number of subjects: 514
Study: 9050699

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen and progesterone postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: No hormone (control group)
Number of subjects: 50
Study: 1880221

Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg BID to a maximum of 400 mg BID over 6 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg or less BID)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Labetalol and Placebo
Number of subjects: 112
Study: 6605127

Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and left ventricular venting through the superior pulmonary vein
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and venting as in Group 1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and no left ventricular vent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and no left ventricular vent
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and with ascending aortic venting through a catheter
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and venting as in Group 5
Number of subjects: 60
Study: 30909779

Group type: EXPERIMENTAL
Intervention: Positive self-statements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head-nodding condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head-shaking condition
Number of subjects: 0
Study: 29162142

Group type: EXPERIMENTAL
Intervention: Concurrent thermochemoradiotherapy (HTCTRT) with locoregional hyperthermia (weekly ×6 during radiotherapy) and concurrent chemoradiotherapy (CTRT) with gemcitabine (400 mg/m2, weekly ×6)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CTRT) alone with gemcitabine (400 mg/m2, weekly ×6)
Number of subjects: 86
Study: 27379509

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, IV)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (saline, IV)
Number of subjects: 65
Study: 24703945

Group type: EXPERIMENTAL
Intervention: Regional palliative care intervention program
Number of subjects: 859
Study: 22818725

Group type: EXPERIMENTAL
Intervention: Dried apple (75 g/day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Dried plum (comparative control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dried apple and dried plum
Number of subjects: 160
Study: 20118174

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n = 2220)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Combination of metformin and sulfonylurea (n = 2227)
Number of subjects: 4447
Study: 18343266

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study: 15911461

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Clomiphene plus Metformin
Number of subjects: 678
Study: 12583464

Group type: EXPERIMENTAL
Intervention: Nitric oxide and lipid peroxides plasma concentrations; superoxide dismutase activity in RBC membranes
Number of subjects: 0
Study: 10508816

Group type: EXPERIMENTAL
Intervention: Educational program for peer groups of doctors
Number of subjects: 0
Study: 8478821

Group type: EXPERIMENTAL
Intervention: Autogenic therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supportive group psychotherapy
Number of subjects: 24
Study: 3102275

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 20 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29426792

Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA (group NAV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional TKA (group CONV)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 26970415

Group type: EXPERIMENTAL
Intervention: PLD-Q questionnaire
Number of subjects: 403
Study: 26187711

Group type: EXPERIMENTAL
Intervention: Follicular phase (low estradiol and progesterone)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Luteal phase (higher estradiol and progesterone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (before TSST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40
Study: 24219416

Group type: EXPERIMENTAL
Intervention: Perceived racial discrimination
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mistrust of medical researchers
Number of subjects: 130

Group type: COMPARATOR
Intervention: Heat pain sensitivity
Number of subjects: 130
Study: 21631478

Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18947029

Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour
Number of subjects: 106
Study: 16864832

Group type: EXPERIMENTAL
Intervention: Bihemispheric motor network reorganization
Number of subjects: 10
Study: 12616672

Group type: EXPERIMENTAL
Intervention: Rofecoxib (250.0 mg/day for 14 days)
Number of subjects: 12
Study: 10704631

Group type: EXPERIMENTAL
Intervention: Plasma from patients with 83+/‐4% stenosis
Number of subjects: 105

Group type: COMPARATOR
Intervention: Plasma from controls with added synthetic oxysterols
Number of subjects: 105
Study: 9794089

Group type: EXPERIMENTAL
Intervention: Magnesium orotate 3 x 1 g
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7834732

Group type: EXPERIMENTAL
Intervention: Multipurpose‐SM catheter
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 3137607

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31786126

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 0

Group type: COMPARATOR
Intervention: γ‐glutamyltransferase levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol consumption, alcohol dependence, AUDIT scores
Number of subjects: 0
Study: 28436694

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control
Number of subjects: 211
Study: 27503262

Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (CT) scan assisted-navigation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Free-hand fluoroscopy-guided surgery
Number of subjects: 114
Study: 26119654

Group type: EXPERIMENTAL
Intervention: On-statin resistin levels
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: On-statin leptin levels
Number of subjects: 352
Study: 23924165

Group type: EXPERIMENTAL
Intervention: Early surgical decompression (within 24 hours after admission)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed surgery (later than two weeks)
Number of subjects: 100
Study: 21099129

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide treatment for 3 months before surgery
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Long-acting octreotide treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (surgery directly)
Number of subjects: 39
Study: 18262147

Group type: EXPERIMENTAL
Intervention: 200 microg of vaginal misoprostol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16700996

Group type: EXPERIMENTAL
Intervention: Head hypothermia treatment
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no head hypothermia)
Number of subjects: 124
Study: 12974974

Group type: EXPERIMENTAL
Intervention: Hand-held echocardiography (HHE)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional transthoracic echocardiography (TTE)
Number of subjects: 103
Study: 11250719

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonists with low-dose hormone replacement
Number of subjects: 0
Study: 8666622

Group type: EXPERIMENTAL
Intervention: Finger packing
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retrograde gun cementing
Number of subjects: 30
Study: 1403273

Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study: 30824830

Group type: EXPERIMENTAL
Intervention: ABBI training (experimental group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Classical training (control group)
Number of subjects: 44
Study: 29485324

Group type: EXPERIMENTAL
Intervention: Protein Supplement (PRO, 42 g/serving)
Number of subjects: 51
Study: 27243611

Group type: EXPERIMENTAL
Intervention: Daily music training for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: French language training for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both training types
Number of subjects: 0
Study: 23291502

Group type: EXPERIMENTAL
Intervention: Twin Block (TB)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dynamax (Dx)
Number of subjects: 103
Study: 22288685

Group type: EXPERIMENTAL
Intervention: Four-dose hydrocortisone regimen (10 + 10 + 5 + 5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Two-dose hydrocortisone regimen (20 + 0 + 10 + 0 mg)
Number of subjects: 15
Study: 19815044

Group type: EXPERIMENTAL
Intervention: Positive mood enhancement (comedy movie clip)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 106
Study: 18478944

Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.3 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.4 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.5 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60
Study: 15560968

Group type: EXPERIMENTAL
Intervention: Ketamine (0.6 mg/kg/h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study: 12084590

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study: 9930787

Group type: EXPERIMENTAL
Intervention: Entrobar
Number of subjects: 56

Group type: COMPARATOR
Intervention: E-Z-Paque
Number of subjects: 56
Study: 8524979

Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) at doses of 1.5 micrograms/kg and 2.5 micrograms/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) at doses of 5 mg and 10 mg
Number of subjects: 0